BioSpace News Archive

EIP Pharma Inc., announces that the final results of the AscenD-LB phase 2 clinical study of their oral investigational drug, neflamapimod, in mild-to-moderate dementia with Lewy bodies were presented today at the 14th Clinical Trials in Alzheimer’s Disease (CTAD) meeting.

Athira Pharma, Inc. today announced that Hans Moebius, M.D., Ph.D., Chief Medical Officer at Athira, presented an overview and updates from two ongoing late-stage clinical trials (ACT-AD and LIFT-AD) with Athira’s lead development candidate ATH-1017 in mild-to-moderate Alzheimer’s disease

CPhI Worldwide – hosted in-person at Fiera Milano, Italy (9-11 November, 2021) – opens its doors to international pharma for the first time in two years as industry confidence surges to record highs according to executives in the CPhI Annual Survey.

Merus N.V., a clinical-stage oncology company developing innovative, full-length multispecific antibodies, announced that Bill Lundberg, M.D., Chief Executive Officer of Merus, will participate in a fireside chat at the Jefferies London Healthcare Conference.

Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics, today reports financial results for the third quarter and nine months ended September 30, 2021, along with an update on the company’s key developments, business operations and upcoming milestones.

Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that Anna Protopapas, President and Chief Executive Officer, will present a company overview at the Stifel 2021 Virtual Healthcare Conference.

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Spanish Agency of Medicines and Medical Devices (AEMPS) has authorized the expansion of the Company’s Phase IIb trial evaluating AllocetraTM in severe and critical COVID-19 patients with acute respiratory distress syndrome (ARDS) to sites in Spain.

Centene Corporation (NYSE: CNC) announced today it will present at the Wolfe Research Virtual Healthcare Conference, to be held November 17-18, 2021 .

SOFIE Biosciences (SOFIE), an established US manufacturer and developer of radiopharmaceuticals, has received clearance to proceed with its Fibroblast Activation Protein Inhibitor (FAPI) clinical trial after completing a 30-day IND review with the FDA.

Amyris, Inc., a leading synthetic biotechnology company accelerating the world to sustainable consumption through its Lab-to-MarketTM operating platform, announced that it has priced $600.0 million aggregate principal amount of 1.50% convertible senior notes due 2026.